
Defining "Value" in Oncology: Experts Weigh in on Frameworks
Rising costs in cancer care have fueled a national conversation on how to decide whether today’s new therapies are “worth it.” A supplement of Evidence-Based Oncology features interviews with those developing value frameworks and coverage of the Oncology Stakeholders Summit, which included patient advocacy, payers and pharmaceutical manufacturers.
FOR IMMEDIATE RELEASEMay 16, 2016
PLAINSBORO, N.J.—The quest to define “value” in cancer care, beyond a simple calculation of outcome and cost, has taken center stage at leading professional meetings and in the public arena. Not long ago, the cost of therapy was off-limits in talks between doctor and patient, but today’s question is: what tools can we bring to the discussion?
A new supplement to
Edited by EBO Managing Editor Surabhi Dangi-Garimella, PhD, the issue includes her interviews with:
· Peter Bach, MD, MAPP, director, Center for Health and Policy Research at Memorial Sloan-Kettering Cancer Center, who is the force behind the DrugAbacus.
· Richard Schilsky, MD, FACP, FASCO, chief medical officer for the American Society of Clinical Oncology (ASCO), who discussed the ASCO Value Framework.
· Steven D. Pearson, MD, MSc, FRCP, founder and president of the Institute for Clinical and Economic Review (ICER), whose evidence reports are aimed mostly at payers.
The supplement also includes an essay by the University of Chicago’s Rena M. Conti, PhD, “Value in Cancer Care: An Economist’s Perspective,” which examines the effect of alternate payment models on care delivery. For the full supplement, click
Coverage of the AJMC Peer Exchange, “Oncology Stakeholders Summit: Considerations for Designing ‘Value Calculators’ for Oncology Therapies,” summarizes the session moderated by Bruce Feinberg, DO, vice president and chief medical officer of Cardinal Health Specialty Solutions, which can be found online
· Alan Balch, PhD, chief executive officer, Patient Advocate Foundation
· James C. Gilroy, senior director for Market Access, Eli Lilly & Co.
· Ira Klein, MD, MBA, FACP, senior director, Quality, Strategic Consumer Group, Janssen Pharmaceuticals.
· Michael A. Kolodziej, MD, national medical director, Oncology Solutions, Aetna.
· Ted Okon, MBA, executive director, Community Oncology Alliance.
About the Journals and AJMC.com
The American Journal of Managed Care is the leading peer-reviewed journal dedicated to issues in managed care.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.